Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

36.44 +1.12 (+3.17%)
Streaming Delayed Price Updated: 10:37 AM EDT, Jul 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Harmony Biosciences Holdings (NASDAQ:HRMY): A Value Stock with Strong Financial Health ↗
Via Chartmill
News headline image
Harmony (HRMY) Q1 2026 Earnings Transcript ↗
Harmony (HRMY) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
A Healthcare Fund Just Made Bitgo Its Biggest Bet ↗
Bitgo Holdings provides digital asset infrastructure and custody services for institutional clients, supporting secure management at scale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A beaten-down biotech just lost a meaningful backer — should you care? ↗
Harmony Biosciences develops therapies for rare neurological disorders, with WAKIX addressing excessive sleepiness in narcolepsy patients. 
Via The Motley Fool
Topics Regulatory Compliance
Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 Revenue Meets Guidance, But EPS Miss and Elevated Spending Weigh on Shares ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY): A Decent Value Play with Strong Fundamentals ↗
Via Chartmill
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total... 
Via MarketMinute
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has... 
Via MarketMinute
Topics Intellectual Property
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Quality at a Discount ↗
Via Chartmill
News headline image
Harmony Biosciences (HRMY) Earnings Transcript ↗
Harmony Biosciences (HRMY) Earnings Transcript 
Via The Motley Fool
Harmony Biosciences Holdings (NASDAQ:HRMY) Reports Q4 2025 Revenue In Line, Earnings Miss Amid Pipeline Investment ↗
Via Chartmill
Topics Earnings
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Compelling Value and Growth Pick ↗
Via Chartmill
News headline image
HRMY Stock Rises On Fresh FDA Approval For Wakix Tablets In Children But Wall Street Eyes Further Rally ↗
The FDA has approved Harmony’s Wakix tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy. 
Via Stocktwits
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime GARP Investment ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Combines Strong Fundamentals with Bullish Technical Setup ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Embodies the Affordable Growth Strategy ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value and Quality Investment Case ↗
Via Chartmill
News headline image
Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity ↗
This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested,... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800 ↗
This bioscience company has had promising financials, yet one of its top executives exited his entire direct equity ownership in mid-January 2026. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800 ↗
This bioscience company has had promising financials, yet one of its top executives exited her entire direct equity ownership in mid-January 2026. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
How Harmony Biosciences Can Prove Its Skeptics Wrong ↗
The biotech company is looking for multiple successes in the coming years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? ↗
Some investors haven't gotten answers to their questions about the biotech stock's past and future. 
Via The Motley Fool
Topics Initial Public Offering Intellectual Property
News headline image
I Was Shocked to Find This Value-Priced Biotech Growth Stock ↗
But deciding if it's a good buy takes a little more looking. 
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗
Harmony Biosciences (HRMY) exemplifies Growth at a Reasonable Price (GARP) with strong sales growth, robust profitability, and a solid financial base, all at a compelling valuation. 
Via Chartmill
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Case ↗
Harmony Biosciences (HRMY) presents a classic value investing case with strong profitability, a healthy balance sheet, and solid growth—all at a compellingly low valuation. 
Via Chartmill
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Growth at a Reasonable Price ↗
Harmony Biosciences (HRMY) is a top GARP stock with strong growth, stellar profitability, and a surprisingly cheap valuation. A compelling growth at a reasonable price pick. 
Via Chartmill
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Appears Undervalued with Strong Fundamentals ↗
Harmony Biosciences (HRMY) appears undervalued with a low P/E ratio, strong profitability, and impressive growth, suggesting a potential market opportunity. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.